MX2024007066A - Uso de amivantamab para tratar el cancer colorrectal. - Google Patents
Uso de amivantamab para tratar el cancer colorrectal.Info
- Publication number
- MX2024007066A MX2024007066A MX2024007066A MX2024007066A MX2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A
- Authority
- MX
- Mexico
- Prior art keywords
- colorectal cancer
- amivantamab
- antibody
- treat colorectal
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287557P | 2021-12-09 | 2021-12-09 | |
| US202163290765P | 2021-12-17 | 2021-12-17 | |
| PCT/IB2022/061991 WO2023105479A1 (en) | 2021-12-09 | 2022-12-09 | Use of amivantamab to treat colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007066A true MX2024007066A (es) | 2024-06-21 |
Family
ID=84537874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007066A MX2024007066A (es) | 2021-12-09 | 2022-12-09 | Uso de amivantamab para tratar el cancer colorrectal. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230183360A1 (https=) |
| EP (1) | EP4444426A1 (https=) |
| JP (1) | JP2025500784A (https=) |
| KR (1) | KR20240112963A (https=) |
| AU (1) | AU2022407875A1 (https=) |
| CA (1) | CA3241933A1 (https=) |
| IL (1) | IL313410A (https=) |
| MX (1) | MX2024007066A (https=) |
| WO (1) | WO2023105479A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547867A (zh) * | 2024-01-16 | 2025-12-16 | 美商健生生物科技公司 | 使用阿米維單抗治療結腸直腸癌 |
| WO2026022733A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
| WO2026022739A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| SG11202108311RA (en) * | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| PH12022552076A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Biotech Inc | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS |
-
2022
- 2022-12-08 US US18/077,318 patent/US20230183360A1/en not_active Abandoned
- 2022-12-09 IL IL313410A patent/IL313410A/en unknown
- 2022-12-09 MX MX2024007066A patent/MX2024007066A/es unknown
- 2022-12-09 WO PCT/IB2022/061991 patent/WO2023105479A1/en not_active Ceased
- 2022-12-09 CA CA3241933A patent/CA3241933A1/en active Pending
- 2022-12-09 KR KR1020247022472A patent/KR20240112963A/ko active Pending
- 2022-12-09 AU AU2022407875A patent/AU2022407875A1/en active Pending
- 2022-12-09 JP JP2024534144A patent/JP2025500784A/ja active Pending
- 2022-12-09 EP EP22826446.1A patent/EP4444426A1/en active Pending
-
2025
- 2025-01-17 US US19/028,911 patent/US20250257139A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023105479A1 (en) | 2023-06-15 |
| US20250257139A1 (en) | 2025-08-14 |
| AU2022407875A1 (en) | 2024-07-25 |
| KR20240112963A (ko) | 2024-07-19 |
| IL313410A (en) | 2024-08-01 |
| CA3241933A1 (en) | 2023-06-15 |
| EP4444426A1 (en) | 2024-10-16 |
| US20230183360A1 (en) | 2023-06-15 |
| JP2025500784A (ja) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007066A (es) | Uso de amivantamab para tratar el cancer colorrectal. | |
| CL2024001384A1 (es) | Moleculas de anticuerpo y conjugados | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| CL2022000495A1 (es) | Formulaciones farmacéuticas y regímenes de dosificación para proteínas de unión multiespecíficas que se unen a her2, nkg2d y cd16 para el tratamiento del cáncer | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| CY1117241T1 (el) | Αντισωματα anti-igf | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| FI3665198T3 (fi) | EGFR:ää ja cMET:tä sitovia vasta-aineita | |
| MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| MX2023001556A (es) | Anticuerpos que se dirigen a egfr y uso de los mismos. | |
| MX2019014316A (es) | Un nuevo anticuerpo anti-c-met y uso del mismo. | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| CL2024002974A1 (es) | Anticuerpos monoclonales y anticuerpo biespecifico contra c-met | |
| MX2023002104A (es) | Composiciones y métodos para tratar cánceres positivos para egfr. | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2018001095A (es) | Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico. | |
| MX2022000779A (es) | Anticuerpo monoclonal anti-vegf humanizado. | |
| AR129232A1 (es) | Anticuerpos triespecíficos cd3 / bcma / cd38 |